#ACR23 Abstr#2335 A step towards equal access to therapy for ANA+ people with arthritis. A cohort study showed: ANA+ (#SLE, #sjogren, MCTD, UCTD) & arthritis were homogenous related to clinical features, PROs & gene expression score. Offer rationale for basket trial @RheumNow https://t.co/7HTMxE7mSP

HCQ discontinuation in SLE? Why?! In this retro cohort of 42 pts Reasons: Retinal toxicity (57%) Self-discontinuation (17%) Factors strongly assoc'd w/ flares 1 yr after discontinuation - mean C3 and +dsDNA at index visit. #ACR23 ABST2343 @RheumNow https://t.co/BCO9N4gSkX

Im usually super shy on camera but my hair looks great in this video with my friend @RHEUMarampa as we talk about how our reviewer went from a personal project to a fellow study resource. #ACR23 #ACRambassador @RheumNow @cerego https://t.co/KHDni7epFK

Pain experience in #OA may have different contributing factors Its a while joint disease! What are the future targets in #OA being tested? @RheumNow #ACR23 @Tuhina_Neogi https://t.co/lI06pJrdYR

GCs on MACE in RA in VA A#2430 #ACR23 @RheumNow Not just ongoing steroid usage, also prior usage 1 year ago 5 mg use for 30 days one year ago - increases MACE events by 3% 5 mg use for 90 days one year ago - increases MACE events by 9%

Wallace et al. Dose, duration, recency dependent relationship between GC and MACE. Even 5mg/day, 30 day use, and use 1 year prior associated with risk. 5mg, 7.5mg, 10mg pred for 90 days - 13%, 19%, 27% MACE increase Abstr#2430 #ACR23 #ACRbest @RheumNow https://t.co/50B5nGqxu9 https://t.co/lNrUbZOm0o

Even low doses of steroids associated with major adverse cardiovascular events! Large VA database - >18k RA pts Dose as low as 5mg/day prednisone for 30 days, 1 year prior to event, associated with increased MACE @RheumNow #ACR23 Abs#2430 https://t.co/JjeoBi7YTD

Mok et al. Romosozumab superior to denosumab in high risk GIO. Superior in improving spine BMD. Not fracture. Fracture is what matters. Abstr#2429 #ACR23 @RheumNow https://t.co/5ModHOGsED

A#2429 #ACR23 @RheumNow ROMO v DEN - 12 mo RCT 70 GIOP pts at high-risk Mean prednisolone dose 6.6 mg H/o fragility fx in 1/2 pts 12 mo: Increase in spine BMD- ROMO (+7) and DEN (+2) Hip and Femoral neck improved both (1.6% both), not signif diff bw grps AEs: incr injxn site rxn https://t.co/VueuZIjFfM

Physical therapy and lifestyle counseling the main pillars of #OA management are underutilized! Mainstay remains weight loss and exercise! @RheumNow #ACR23 Rrf memorial lecture @Tuhina_Neogi https://t.co/yXqWIEccq4

McCormick et al. No improvement in premature mortality gap in gout over time. 19% increased mortality in gout. Independent of serum urate and CV risk factors. Abstr#2428 #ACR23 @RheumNow https://t.co/lSoEvajN3O https://t.co/uWNokm7LCT

Gout mortality A#2428 #ACR23 @RheumNow 1988-1994 (early) v 2007-2016 (late): Has not improved over time Independent of serum uric acid Female gout: increased mortality Black gout pts also increased Conclusion: the inflammation, not the uric acid is the risk https://t.co/LTFoSFzaBu

The DICKENS study showed no significant improvement in knee pain(p=0.77), WOMAC pain(p=0.64) or function(p=0.68) & stiffness(p=0.34) between diacerin and pbo over 24wks. ⬆️AEs in diacerin grp-diarrhea, colored urine #ACR23 ABSTL05 @RheumNow https://t.co/ht0pGN38il

Super interesting SpA phenotypical type world map. #ACR23 Abs #2195 continues to prove how heterogenous this disease is and the need for additional therapeutic agents for improved patient outcomes. https://t.co/hpKY7usUUb @rheumnow https://t.co/xJ1bx6wOC0

A#2427 #ACR23 @RheumNow PR3+ cell abundance higher in prolif LN, more than membranous. Mostly in tuberulointerstitium Density of PR3+ higher in glomueruli of prolif LN Correlates with activity, not chronicity Urinary PR3 predict renal fxn loss at 3y @jhrheumatology @andreafava https://t.co/vvC8lgZgWO